Stock of the Day

March 4, 2020

Bruker (BRKR)

$56.54
+$0.94 (+1.7%)
Market Cap: $8.47B

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Today's Trend

Bruker Corporation (NASDAQ: BRKR) shares remain under pressure following mixed second-quarter results and concerns about weak growth in the company’s primary market. The stock is trading below its 50-day moving average, although it remains above its 200-day average.

  • Zacks upgraded Bruker from “hold” to “strong-buy,” providing a favorable analyst signal that could support investor sentiment. Zacks.com
  • Management highlighted margin strength during the second-quarter earnings call. Bruker also reported adjusted earnings of $0.49 per share, exceeding the $0.38 analyst consensus, while revenue increased 5.2% year over year. Bruker Corporation Earnings Call Highlights Margin Strength
  • Citigroup lowered its price target from $60 to $53 and maintained a “neutral” rating. The revised target implies limited upside from the current trading level, signaling reduced confidence in near-term appreciation. Benzinga
  • Second-quarter revenue of $838.5 million fell short of the $853.6 million consensus estimate. The sales miss triggered a sharp selloff, despite the earnings beat, as investors focused on weaker-than-expected demand. Bruker Q2 2026 Earnings
  • Analysts continue to cite weak growth in Bruker’s primary market as a significant overhang, raising concerns about the pace of future revenue expansion. Weak Growth in Bruker’s Primary Market

Overall, BRKR’s earnings beat and margin performance are being outweighed by the revenue shortfall and market-growth concerns. Bruker maintained fiscal 2026 EPS guidance of $2.10 to $2.15, keeping expectations centered on whether demand improves in coming quarters.

Recent News